Castle Biosciences Presents Three New Clinical Studies at ASCO 2017 Highlighting the Accuracy and Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Cutaneous Melanoma | Prospective, multicenter study confirms prognostic accuracy and performance | Newly expanded cohort shows promise in prognosis of Stage III melanoma
Category Archives: AZBio News
FDA Approves VENTANA ALK (D5F3) Assay as a companion diagnostic for ZYKADIA.
On June 1, 2017, Roche (SIX: RO, ROG; OTCQX:RHHBY) announced US Food and Drug Administration (FDA) approval of the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Novartis drug ZYKADIA (ceritinib). The VENTANA ALK (D5F3) Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for ZYKADIA.Continue reading
Parkinson’s Awareness Has Grown Since Muhammad Ali’s Death
Barrow survey shows strong identification with fight against Parkinson’s disease
Diverse group of TB stakeholders share and learn about new developments in TB drug and drug susceptibility testing research
The CPTR Initiative continues to demonstrate its value and role in accelerating the development of new TB regimens and drug susceptibility testing (DST), as well as tools to help drive and focus research efforts. Various CPTR members and TB stakeholders reflect on the breadth and value of CPTR and its annual Workshop.Continue reading
TD2 and Deep 6 AI Announce Partnership to Accelerate Oncology Clinical Trial Recruitment
Artificial intelligence used to identify potential clinical trial participants in minutesContinue reading
A First for Bad Breath – ClōSYS Receives ADA Seal of Acceptance
Two ClōSYS Alcohol-Free Oral Health Rinses are the first mouth rinses to be awarded the ADA Seal of Acceptance for the management of oral malodor. Continue reading
Banner Alzheimer’s Institute Receives Added NIH Support for pioneering Alzheimer’s prevention trial in Medellin
Banner Alzheimer’s Institute Receives Added NIH Support – Five-year funding expected to total $14.8 million to support groundbreaking Alzheimer’s Prevention InitiativeContinue reading
Mara Aspinall elected to Allscripts Board of Directors
Allscripts shareholders elected biotech industry executive Mara G. Aspinall to the company’s Board of Directors. Continue reading